{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:10Z","timestamp":1786119490648,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1097\/01.mcp.0000370208.45756.e8","type":"journal-article","created":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T04:21:44Z","timestamp":1270095704000},"page":"S27-S34","source":"Crossref","is-referenced-by-count":16,"title":["Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease"],"prefix":"10.1097","volume":"16","author":[{"given":"J Gerry","family":"Coghlan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210206","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/ard.62.11.1088","article-title":"Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach","volume":"62","author":"Mukerjee","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R2-4-20210206","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s002960050074","article-title":"Pulmonary hypertension in systemic lupus erythematosus","volume":"18","author":"Shen","year":"1999","journal-title":"Rheumatol Int"},{"key":"R3-4-20210206","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1191\/096120300678828361","article-title":"Primary and secondary pulmonary hypertension in systemic lupus erythematosus","volume":"9","author":"Pan","year":"2000","journal-title":"Lupus"},{"key":"R4-4-20210206","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11926-007-0011-4","article-title":"Therapy of pulmonary arterial hypertension in systemic sclerosis: an update","volume":"9","author":"Denton","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"R5-4-20210206","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","article-title":"Connective tissue disease associated pulmonary arterial hypertension in the modern treatment era","volume":"179","author":"Condliffe","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"R6-4-20210206","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cardiores.2003.11.026","article-title":"The endothelin system in pulmonary arterial hypertension","volume":"61","author":"Gali\u00e8","year":"2004","journal-title":"Cardiovasc Res"},{"key":"R7-4-20210206","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1136\/hrt.2005.069484","article-title":"Systemic sclerosis associated pulmonary hypertension: improved survival in the current era","volume":"92","author":"Williams","year":"2006","journal-title":"Heart"},{"key":"R8-4-20210206","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2174\/092986707780059562","article-title":"Current drug targets and future therapy of pulmonary arterial hypertension","volume":"14","author":"Ito","year":"2007","journal-title":"Curr Med Chem"},{"key":"R9-4-20210206","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"R10-4-20210206","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"R11-4-20210206","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R12-4-20210206","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1378\/chest.126.2.420","article-title":"Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease","volume":"126","author":"Oudiz","year":"2004","journal-title":"Chest"},{"key":"R13-4-20210206","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial","volume":"39","author":"Gali\u00e8","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R14-4-20210206","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension","volume":"41","author":"Barst","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R15-4-20210206","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"R16-4-20210206","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"R17-4-20210206","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial","volume":"371","author":"Gali\u00e8","year":"2008","journal-title":"Lancet"},{"key":"R18-4-20210206","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/ard.2005.048967","article-title":"Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions","volume":"65","author":"Denton","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R19-4-20210206","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1136\/ard.2007.079921","article-title":"Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.","volume":"67","author":"Denton","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"9 Suppl","key":"R20-4-20210206","first-page":"1199","article-title":"Long-term effects of bosentan treatment on survival in patients with pulmonary arterial hypertension (PAH) related to connective tissue disease (CTD)","volume":"56","author":"Pope","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R21-4-20210206","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"R22-4-20210206","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan","volume":"47","author":"Barst","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R23-4-20210206","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/ard.2007.069609","article-title":"Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease","volume":"66","author":"Girgis","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R24-4-20210206","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"key":"R25-4-20210206","doi-asserted-by":"crossref","first-page":"488S","DOI":"10.1378\/chest.132.4_MeetingAbstracts.488b","article-title":"Ambrisentan therapy for pulmonary arterial hypertension: a comparison by PAH etiology","volume":"132","author":"Badesch","year":"2007","journal-title":"Chest"},{"key":"R26-4-20210206","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N Engl J Med"},{"key":"R27-4-20210206","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"key":"R28-4-20210206","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-136-7-200204020-00008","article-title":"Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension","volume":"136","author":"Ghofrani","year":"2002","journal-title":"Ann Intern Med"},{"key":"R29-4-20210206","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"key":"R30-4-20210206","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1183\/09031936.05.00075305","article-title":"Goal-oriented treatment and combination therapy for pulmonary arterial hypertension","volume":"26","author":"Hoeper","year":"2005","journal-title":"Eur Respir J"},{"issue":"Abstracts Issue","key":"R31-4-20210206","first-page":"A965","article-title":"TRIUMPH I: efficacy and safety of inhaled treprostinil sodium in patients with pulmonary arterial hypertension (PAH)","volume":"177","author":"McLaughlin","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R32-4-20210206","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R33-4-20210206","first-page":"2417","article-title":"Sildenafil for pulmonary arterial hypertension associated with connective tissue disease","volume":"34","author":"Badesch","year":"2007","journal-title":"J Rheumatol"},{"key":"R34-4-20210206","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)","volume":"30","author":"Gali\u00e8","year":"2009","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"R35-4-20210206","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/hrt.2007.132118","article-title":"Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland.","volume":"94","year":"2008","journal-title":"Heart"}],"container-title":["Current Opinion in Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.mcp.0000370208.45756.e8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:21:21Z","timestamp":1786040481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00063198-201005001-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":35,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/01.mcp.0000370208.45756.e8","relation":{},"ISSN":["1070-5287"],"issn-type":[{"value":"1070-5287","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}